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ABSTRACT  
Objective: Curcumine (CUR) and rapamycin (RAPA) are two potent hydrophobic anticancer drugs. The clinical and preclinical applications of 
anticancer formulations are limited due to use of toxic excipients and poor bioavailability. In the present study, an approach has been made to 
develop CUR and RAPA loaded MePEG/PCL di-block copolymeric micelles keeping in the view to make excipient free formulation with slow release 
of drugs. 
Methods: The CUR and RAPA loaded MePEG/PCL di-block copolymeric micelles were prepared. Physico-chemical characters like size, surface 
charge and encapsulation efficiency were measured. The in vitro release studies was carried out in pH 7.4 to evaluate the sustained release 
properties of micelles. 
Results: MePEG/PCL di-block copolymeric micelles were efficiently encapsulate both the drugs, i. e. CUR (~ 64 %) and RAPA (~ 94 %) in the core 
and have loading capacity of ~ 12 % (CUR) and ~ 29 % (RAPA). The zetasizer measurement shows that particles have size range 128 nm to 176 nm 
with a negative zeta potential. SEM and AFM studies reveled that micelles have smooth exterior surface. The XRD and DSC studies explain that the 
drugs are uniformly distributed in the polymer matrix. The dual drug loaded micelles have sustained in vitro drug release activity as estimated in 
phosphate buffer (pH 7.4).  
Conclusion: These MePEG/PCL di-block copolymeric micelles are capable of carrying both the hydrophobic anticancer drugs and the encouraging 
results suggest further studies to evaluate the bioavailability parameters as well as suitability of the formulation. 
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INTRODUCTION 
Polymeric micelles are nanoscopic core shell structures formed by 
aqueous self assembly of amphiphilic block copolymers [1]. These 
micelles have hydrophobic core surrounded by hydrophilic outer 
shell. The inner core of the micelles is used for the encapsulation of 
poorly water soluble drugs and the outer core can be modified with 
heterogenous functionalities to facilitate drug loading and targeting. 
Over the past few years, block copolymeric micelles have been used 
as drug carriers for poorly water-soluble drugs that result in 
improved bioavailability, prolonged plasma circulation and 
decreased systemic toxicity of drugs. In addition to the rapid 
clearance by the reticuloendothelial system resolved the passive 
targeting of certain tissues through the enhanced permeation and 
retention (EPR) effect. These properties along with established 
safety record in humans has lead to a research encouraging it as an 
alternate to commercial anticancer formulations [2, 3]. Micelles 
characters can be influence by the monomers, chain architecture, 
composition, molecular weight and the method employed to 
disperse amphiphiles in to the desired media [4]. 
The poor water soluble drugs require safe vehicles for drug 
solubilization and intravenous infusion. The commonly used 
excipients (i. e. Cremophor EL, DMSO, phosphatidylcholine or 
ascorbyl palmitate etc.) For intravenous drug infusion are often 
toxic and obstruct the progress in therapy involving hydrophobic 
anticancer drugs. The excipients used in therapy involving more 
than one drug had run the risk of precipitation and additive toxicity 
caused by vehicles used for drug solubilization. For example, 
hypersensitivity reaction occurs in patients that receive Cremophor 
EL despite premedication with corticosteroids and histamine 
antagonists [5]. Other serious toxicities associated with Cremophor 
EL use include nephrotoxicity and neurotoxicity [6-8]. Thus, there is 
need to find alternate formulations and vehicles to deliver these 
agents without contributing to the side effects experienced by 
patients on chemotherapy. Various copolymeric micelles have 
shown monotherapeutic approach for delivery of anticancer agents 
like paclitaxel, docetaxel, rapamycin, doxorubicin, etoposide and 
curcumin [9-11]. The block copolymeric micelles of methoxy 
poly(ethylene glycol) (MePEG)/poly(ε-caprolactone) have high taxol 
loading capacity and can be used for anticancer activity in vivo male 
ICR mice model [12]. Due to the effectiveness of micellar system, 
PEG-b-PLA micelles loaded with paclitaxel (Genexol-PM) are 
approved in Korea for cancer treatment, and are also in phase II 
clinical trials in USA [13].  
The heterogeneity of cancer cells and acquired drug resistance limits 
the single agent therapy and increases the possibility to use 
combinational chemotherapy and combating factors associated with 
multidrug resistance (MDR) [14]. Synergistic drug combinations 
produce an even greater response rate or survival time than is 
possible with each drug used alone at its optimum dose. For 
multidrug based cancer therapy, micelles provide a good platform to 
co-administer anticancer therapeutics for solubilization of 
hydrophobic drugs, sustained drug release activity, thereby 
allocating modulation of the pharmacokinetics properties and 
biodistribution of the drug [15].  Shin et al. Has developed PEG-b-
PLA micellar system for combinational approach involving a 
chemotherapeutic drug and molecularly targeted agent, which 
provide a better approach for combination cancer therapy [16]. 
Therefore, in the present study, we prepared a combinational 
formulation of CUR and RAPA loaded in MePEG/PCL diblock 
copolymers and explored its physico-chemical properties [9]. 
MATERIALS AND METHODS  
Materials 
CUR-500, containing Curcumin (> 95 %) was purchased from UNICO 
Pharmaceuticals (Ludhiana, India). Rapamycin (97 % trans and 3 % 
cis enantiomer) was purchased from Fujian Kerui Pharmaceutical 
Co. Ltd., China. Methoxy poly (ethylene glycol) (MePEG, Mn= 5000 by 
supplier, Mn= 5541 by our GPC measurements), Caprolactone (ε-CL) 
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Synthesis of MePEG/ ε-CL diblock copolymers 
=114.14) was supplied by Fluka (Sigma-Aldrich, Saint Louis, 
MO) and used after proper purification. All other reagents were of 
analytical grades and used without further purification. Distilled- 
deionized water was prepared with Milli-Q plus System (Elix 10, 
Millipore corp. India). 
MePEG/PCL diblock copolymers with molar ratios (60:40) were 
synthesized as described in our previous paper [10]. In brief, the 
MePEG was activated by azeotropic distillation with toluene. 
MePEG/PCL diblock copolymers were synthesized by ring opening 
polymerization of PCL using MePEG homopolymer as micro initiator 
and Sn(Oct)2
Encapsulation of CUR and RAPA in MePEG/PCL micelles 
 as a catalyst. The predetermined ratios of both the 
polymer were mixed in a round bottom flask, degassed and kept at 
160 °C. When the polymerization was completed, the reaction 
product was cooled at an ambient temperature, and then dissolved 
in dichloromethane to remove MePEG homopolymers and any 
residual caprolactone monomers. The precipitate was collected by 
filtration and washed several time with diethyl ether and the 
resultant product was dried in a vacuum oven at 40 °C for 3 days. 
The final diblock copolymer synthesized by the above protocol was 
characterized by NMR and GPC and found to same as reported in our 
earlier publication [10]. 
Diblock copolymeric micelles containing either single drug (CUR or 
RAPA) or dual drugs (CUR+RAPA) were prepared by a modified 
dialysis method [11]. Briefly, 100 mg of MePEG/PCL diblock 
copolymers were dissolved in 10 ml of dimethylformamide, to that 
10 mg of either CUR or RAPA for single drug formulation and a 
mixture of 5 mg of CUR and 5 mg of RAPA was added for dual drug 
loaded formulation and stirred at room temperature. The solution 
mixture was dialyzed for 24 h against 3 liters of ultrapure water 
using cellulose dialysis membranes (molecular weight cutoff: 12 
kDa, average diameter 21 mm and average flat width 35 mm, as 
supplied, Sigma). The water was changed three-times during the 
dialysis process. The micellar solution from dialysis bag was 
collected and sonicated by using sonicator (VC 505, Vibracell Sonics, 
Newton) of energy output set at 55 W for 1 min in an ice bath. The 
obtained micellar solution was lyophilized by freeze drying method 
(-80 °C and <10 mm mercury pressure, Freezone 6lt, Labconco 
Corp., MO) to get lyophilized powder for further use. 
Particle size analysis & zeta potential measurement 
Hydrodynamic mean particle size distribution and surface potential 
of the drug loaded micelles were determined by Photon Correlation 
Spectroscopy and Laser Doppler Anemometry, respectively, using 
Nano ZS (Malvern Instruments, Worcestershire, UK). Size 
measurements were performed by taking the drug loaded micelles 
(~1 mg/ml) in Milli-Q water at 25 °C and sonicated for 30 s in an ice 
bath (VC 505, Vibracell Sonics, Newton, USA) and further diluted 
with MilliQ water (100 µl diluted to 1 ml). The same suspension was 
used for measuring the ζ potential of drug loaded micelles by using 
the same equipment.  
Quantification of entrapment efficiency by RP-HPLC method 
The entrapment efficiency of different drugs in the micellar 
formulation (either single or dual) was determined by Reverse 
Phase High Performance Liquid Chromatography (RP-HPLC) method 
[10]. Briefly, 10 mg of the lyophilized drug loaded micelles were 
dissolved in 5 ml of acetonitrile, sonicated for 2 min in an ice bath 
(VC 505, Vibracell Sonics, Newton, USA) centrifuged at 13,800 rpm 
for 10 min at 25 °C (Sigma 1-15K, Osterode, Germany) to get a clear 
supernatant, which was then analyzed by using a isocratic mode of 
RP-HPLC system of Agilent-1100 (Agilent Tech. Waldbronn 
Analytical Division, Germany) with C18 column (Zorbax Eclipse 
XDB-C18, 150× 4.6 mm ID) having internal standard of 
dimethylphthalate. Using the mobile phase of acetonitrile and 
water in 80:20, v/v ratio, both the drugs were quantified with 
their respective wavelengths. For this, 20 μl of the sample was 
injected manually in the injection port and analyzed at a flow 
rate of 1 ml/min using a quaternary pump (Model-G1311A) at 25 
°C with Thermostat (Model-G1316A). The estimation of CUR 
level was quantified at 420 nm whereas RAPA was quantified at 
278 nm with absorbance detector (DAD, Model-G 1315A). The 
amounts of CUR and RAPA in drug loaded micelles were 
determined from the obtained area under curve. The standard 
curve of the single drug and in combination was prepared 
separately under identical conditions. The samples (in triplicate) 
were analyzed and the drug encapsulation efficiency (EE) was 
calculated [11]. 
Scanning electron microscopy (SEM) 
The surface morphology of the (CUR+RAPA) loaded micelles were 
characterized by SEM (ZEISS EVO18, Carl Zeiss SMT GmbH, 
Germany) operating at an accelerating voltage of 10-30 kV. The 
micelles were gold coated and placed on a copper stub prior to the 
acquisition of SEM images.  
Atomic force microscopy (AFM)  
The morphology of the (CUR+RAPA) loaded micelles were visualized 
by AFM (JPK nanowizard II, JPK instrument, Berlin, Germany), after 
over night air drying of the micellar solution on a clean mica surface, 
using a pyramidal cantilevers with silicon probes having force 
constants of 0.2 Nm-1
X-ray diffraction (XRD)  
. The shape was observed and imaged using JPK 
data processing software in non contact mode with frequency of 312 
kHz and scan speed of 2 Hz. 
X-ray diffraction studies were carried out to know the 
crystallographic state of the native drugs and to confirm its physical 
state in the micellar formulation. The XRD patterns of the samples 
were obtained by using XRD diffractometry (D8 ADVANCE, 
BrukerAXS Inc, Madison, WI). A monochromator features high flux 
K-α-1 radiation at 40 kV and 100 mA was used. Diffractograms were 
performed with 2θ ranges from 0° to 50° with a step of 0.02°, at a 
scanning speed of 4°/min (2θ). 
Differential scanning calorimetric (DSC)  
The physical states of the dual drug loaded micelles were 
characterized using a differential scanning calorimetric (DSC) 
thermogram analyser (STA 6000 Simultaneous Thermal Analyser, 
Perkin Elmer, Waltham, MA). Briefly, 8 mg of each sample (native 
CUR, native RAPA and (CUR+RAPA) loaded micelles) were sealed 
separately in a standard aluminum pan, and purged with pure dry 
nitrogen gas set at a flow rate of 10 ml/min, the temperature 
variation was set at 10 °C/min, and the heat flow was recorded from 
0 to 350 °C. 
In vitro drug release kinetics study for drug loaded micelles 
In vitro release kinetics of either curcumin or rapamycin from 
the (CUR+RAPA) loaded micellar system was performed by 
dissolving 10 mg of the sample in 3 ml of PBS (0.1 M, pH 7.4, 
containing 0.1 % v/v of Tween 80) [11]. Tween 80 was used to 
maintain the sink condition [10]. The micellar suspension was 
mixed properly by vortexing, and equally divided in three tubes 
containing 1 ml each and kept in orbit shaker rotating at 150 
rpm in 37 °C (Wadegati Lab equip, India). At pre-determined 
time intervals these tubes were taken out from shaker and 
centrifuged at 13,800 rpm, 4 °C for 10 min (SIGMA 1-15K, 
Germany), supernatants were collected, the leftover pellets were 
re-suspended with 1 ml of fresh PBS (0.1 M, pH 7.4) containing 
0.1 % v/v tween 80 solutions and replaced in shaker for further 
samplings.  The collected supernatants were lyophilized for 48 h 
and dissolved in 1 ml of acetonitrile, centrifuged at 13,800 rpm for 
10 min at 10 °C, (Sigma 1-15K, Germany) to collect the drug in 
supernatant. The amount of drug released with respect to different 
time intervals was analysed by RP-HPLC system and all 
measurements were performed in triplicates [10]. 
Statistical analysis 
Statistical analyses were performed using a Student’s t test. The 
values of p < 0.05 (*) were indicative of significant difference and 
very significant difference if p < 0.005 (**). 
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RESULTS  
The dual drugs CUR and RAPA were successfully loaded in the 
MePEG/PCL diblock copolymeric micelles by modified dialysis 
method [10]. The solubility of the drugs in the micelles was 
significantly increased as compared to their intrinsic solubility in 
water. The drug(s) to polymer weight percentage ratio was kept 
constant (10 %) in all formulations.  For all micelle formulations 
approximately 100 % of the initial amount of the drug(s) and 
polymer was recovered as drug loaded MePEG/PCL diblock 
copolymeric micelles. The encapsulation efficiency of (CUR+RAPA) 
loaded micelles as determined by RP-HPLC was found to be ~ 64 % 
(CUR) and ~ 94 % (RAPA), which were not have much significant 
difference from the single drug loaded micelles. Similarly, loading 
capacities of these micelles were nearly equal to single drug loaded 
micelles, as given in Tab. 1. 
Particle size analysis & zeta potential measurement 
The particle size and ζ potential measurement of the micelles by 
dynamic laser light scattering technique accomplished that the 
micelles were having a diameter range ~ 128 to 176 nm along with 
low polydispersity index, implying a narrow size distribution (Fig. 
1a). The hydrodynamic diameters of drug loaded micelles were 
slightly higher than that of void micelle due to incorporation of 
drugs either single or in combination (Tab. 1). PDIs of all 
formulations were below 0.2, indicating narrow particle size 
distribution. The loaded micelles illustrated negative zeta potential 




Fig. 1: (a) Mean particle size of Void micelles, CUR loaded micelles, RAPA loaded micelles and (CUR+RAPA) loaded micelles (data as mean 
± S. E. M; n = 6), (b) Zeta potential of Void micelles, CUR loaded micelles, RAPA loaded micelles and (CUR+RAPA) loaded micelles (data as 
mean ± S. E. M; n = 6). 
 
Table 1: Summary of physico-chemical characterization of MePEG/PCL block copolymeric micelles. (Data represents mean ± SD) 









Void Micelle 128 ± 2.6 0.13 ± 0.008 -11.50 ± 2.77 -- -- 
CUR Micelle 140 ± 2.56 0.28 ± 0.004 -14.8 ± 1.96 60.3 ± 1.73 14 ± 1.7 
RAPA Micelle 145 ± 2.86 0.18 ± 0.004 -15.8 ± 1.26 98.3 ± 1.43 31 ± 1.5 
(CUR+RAPA) Micelle 176 ± 3.06 0.19 ± 0.006 -14.0 ± 2.60 64 ± 2.6 (CUR) 
94 ± 3.4 (RAPA) 
12 ± 2.1 (CUR) 






� =  
Weight of the drug in micelle
Weight of the drug added




� =  
Weight of the drug in micelle
Weight of the polymer and drug added
 × 100 
 Encapsulation efficiency and Loading capacity (expressed as %) were estimated by HPLC. 
Surface morphology studies 
The surface morphology of the (CUR+RAPA) loaded micelle was 
determined using scanning electron microscopy [17]. The SEM 
image of nanoparticles revealed spherical shape with smooth 
surface as shown in Fig. 2a. The atomic force microscopy (AFM) 
investigations showed spherical structure of the particles with slight 
aggregation due to freeze drying of the product as shown in Fig. 2b. 
The microscopic studies also reveal that the micelles were 
surrounded by polymeric soft layer [17].  
X-ray diffraction (XRD)  
XRD analysis was conducted to confirm the physical state of CUR 
and RAPA in (CUR+RAPA) loaded micelles, which suggested that the 
CUR and RAPA were in amorphous form or in the solid state 
solubilized form in the micellar formulation as shown in Fig. 3a [18]. 
Differential scanning calorimetric (DSC)  
The DSC analysis was performed for native CUR, native RAPA, and 
(CUR+RAPA) loaded micelles to found out the physical state of the 
drug inside the micellar formulation as illustrated in Fig. 3b.  
 
Fig. 2: (a) Scanning electron micrograph of (CUR+RAPA) loaded 
micelles (bar = 100 nm), (b) Atomic Force microscopy (AFM) 
images of (CUR+RAPA) loaded micelles. 
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It was observed that the native CUR and native RAPA had an 
endothermic peak of melting point at ~176 °C and ~190 °C 
respectively [19]. These characteristic peaks were absent in the 
(CUR+RAPA) loaded micelles. The absence of the detectable crystalline 
endothermic peak of the CUR and RAPA in the micellar formulation 
clearly indicated that CUR and RAPA encapsulated in the micelles were 
in the form of amorphous or in solid-state solubilized form in the 
polymeric matrix [10]. 
 
Fig. 3: (a) XRD analysis of (I) Native RAPA, (II) Native CUR, (III) 
(CUR+RAPA) loaded micelles, (b) DSC thermogram of (I) Native 
CUR, (II) Native RAPA, (III) (CUR+RAPA) loaded micelles. 
 
In vitro drug release kinetics study 
The release kinetics study was carried out to estimate the amount of 
drug released from the micellar system under in vitro conditions. 
The in vitro release profile of CUR and RAPA from (CUR+RAPA) 
loaded polymeric micelles showed a biphasic release pattern as 
shown in Fig. 4. The observed initial rapid release of drugs might be 
due to diffusion of drugs present at the surface of the micelles and 
the encapsulated drugs inside the core of the micelles showed the 
sustained release [20]. The result was correlated with the CUR and 
RAPA release from the CUR loaded micelles and RAPA loaded 
micelles respectively.  
 
 
Fig. 4: In vitro release kinetics of (a) CUR from the CUR loaded 
micelle, (b) RAPA from RAPA loaded micelle, (c) CUR and RAPA 
from (CUR+RAPA) loaded micelles. The inserts shows the 
percentage cumulative drug release from 1hr to 8 hrs. Data as 
mean ± S. E. M (n = 3). 
DISCUSSION 
GBM is the most common primary malignant brain tumor, having a 
low survival rate despite of available treatments such as surgery, 
radiotherapy and non-invasive chemotherapy. Utilization of 
nanotechnology based drug delivery system are exceptionally 
helpful for the treatment of brain tumors as constant dose of 
anticancer drugs can be delivered directly to cancer tissues [21]. 
Moreover, cancer therapy relying on single therapeutic agent 
remains suboptimal. Therefore, combination of two or more 
therapeutic agents with different working mechanism can 
cooperatively prohibit cancer development, has become one of the 
promising approach for effective cancer treatment [22, 23]. These 
combinations of drugs promote synergism than that of single drug 
against cancer cells and it suppresses drug resistance and increases 
the therapeutic index through distinct mechanisms of action [24].  
In the current study an attempt was taken to explore the micellar 
system to deliver simultaneously two anticancer drugs and 
characterized their physico-chemical properties. Here, two potent 
anticancer drugs, CUR and RAPA were encapsulated successfully in 
MePEG/PCL diblock copolymeric micellar system. The resulting 
(CUR+RAPA) loaded micelles showed high drug encapsulation 
efficiency, uniform smooth particle topology, negative zeta potential 
and sustained release of ∼ 85 % of the drug in two weeks from the 
micellar system, which is an indispensable requirement for cancer 
therapy [25]. The small size of the (CUR+RAPA) loaded micelles 
helps in the passive targeting to tumor tissue by enhanced 
permeability and retention (EPR) effect [26]. The amorphous state 
of the entrapped drug inside the micellar formulation as illustrated 
from XRD and DSC analysis further attributed to the sustained 
release activity of both the drugs. However, the in vitro drug release 
kinetics showed that both CUR and RAPA were released from 
(CUR+RAPA) loaded micelles simultaneously, without affecting each 
other’s release profile. These properties of the drug loaded micelles 
would enhance the bioavailability and circulation half-life upon in 
vivo administration [27]. 
CONCLUSION 
The present study demonstrated that encapsulation of the dual 
drugs CUR and RAPA within the MePEG/PCL diblock copolymeric 
micellar system can increase the therapeutic efficacy of the drug. 
The harsh excipients related severe side effects and the stability 
concerns related to administering combination chemotherapy can 
be circumvented. MePEG/PCL diblock copolymeric micellar system 
offers a novel alternative to the current commercial formulations. 
The formulation was able to improve the physicochemical 
characteristics of both the hydrophobic anticancer drugs and it 
shows slow release of both curcumin and rapamycin simultaneously. 
These physical characteristics and release behavior shows that the 
MePEG/PCL diblock copolymeric micelles were compatible for the 
encapsulation of both the drugs and the formulation may be used for 
further in vitro and in vivo studies. 
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